Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Discontinuation of therapy Clear all
Recruiting Phase 4 Interventional

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

NCT06562543
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Fruquintinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

NCT02426125
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Ramucirumab, Docetaxel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
33
States / cities
Fayetteville, Arkansas • Fullerton, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplant for Immunologic or Histiocytic Disorders

NCT00176865
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Deficiency Syndromes, Langerhans-Cell Histiocytosis
Interventions
Stem Cell Transplant, Fludarabine, Melphalan, Anti-thymocyte globulin (ATG), Campath 1H, Cyclosporin A, Mycophenolate mofetil, Intravenous immunoglobulin (IVIG)
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 28, 2026, 4:01 PM EDT
Terminated Phase 2 Interventional Results available

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

NCT00594230
View directory record Official record
Conditions
Myelodysplastic Syndromes (MDS)
Interventions
Panobinostat
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Fort Myers, Florida • Gainesville, Georgia • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

NCT02208037
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma
Interventions
Tacrolimus (ARM with Methotrexate), Tacrolimus (ARM with MMF and Cyclophosphamide), Methotrexate (ARM with Maraviroc), Methotrexate (ARM with Bortezomib), Maraviroc, Bortezomib, Mycophenolate mofetil, Cyclophosphamide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
30
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 28, 2026, 4:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Interventions
MK-1045
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 4:01 PM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

NCT04191681
View directory record Official record
Conditions
Stage D Heart Failure
Interventions
Sacubitril-Valsartan, Usual care (standard-of-care) arm
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Early Phase 1 Interventional

Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

NCT07069465
View directory record Official record
Conditions
Prostate Cancer
Interventions
flotufolastat F 18, Relugolix 120 MG, Serum PSA and Testosterone
Diagnostic Test · Drug
Lead sponsor
Urology Clinics of North Texas
Network
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 28, 2026, 4:01 PM EDT
Completed No phase listed Observational

Pharmacist-Driven Stress Ulcer Prophylaxis Minimization in the Intensive Care Unit

NCT06225167
View directory record Official record
Conditions
Stress Ulcer
Interventions
To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Telerehabilitation After Shoulder Arthroplasty

NCT05499728
View directory record Official record
Conditions
Arthritis Shoulder Glenohumoral Joint, Rotator Cuff Tear Arthropathy, Arthropathy Shoulder
Interventions
Telerehabilitation; physical therapy via telecommunication device (i.e. online video conferencing)
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 28, 2026, 4:01 PM EDT
Recruiting Phase 2 Interventional

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

NCT03886311
View directory record Official record
Conditions
Sarcoma
Interventions
Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 28, 2026, 4:01 PM EDT
Completed No phase listed Observational

Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy

NCT00625248
View directory record Official record
Conditions
Bleeding
Interventions
Antithrombotics
Drug
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 28, 2026, 4:01 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

NCT00447226
View directory record Official record
Conditions
Cancer
Interventions
Oral lapatinib tablets or placebo tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03014648
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
Atezolizumab
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Orlando, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension

NCT01996449
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone, Amlodipine, Microneurography, Rhythmic handgrip exercise, Sustained hand grip, Forearm blood flow, Arm cycling exercise, Cold Pressor test
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 28, 2026, 4:01 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

NCT02658084
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Vinorelbine, Trastuzumab Emtansine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

NCT04761198
View directory record Official record
Conditions
Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Etigilimab, Nivolumab
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Phoenix, Arizona • Greenbrae, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 28, 2026, 4:01 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
JNJ-78278343
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC

NCT02407171
View directory record Official record
Conditions
Melanoma, Lung Cancer
Interventions
MK-3475, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 1 Interventional

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

NCT04641871
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumor
Interventions
Sym021, Sym022, Sym023, Irinotecan Hydrochloride
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC

NCT02047344
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage IV
Interventions
Antroquinonol
Drug
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Tucson, Arizona • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

NCT02831764
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Sep 28, 2026, 4:01 PM EDT
Terminated Phase 1Phase 2 Interventional

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

NCT02992964
View directory record Official record
Conditions
Refractory or Recurrent Hypermutated Malignancies, Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
Interventions
Nivolumab
Drug
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
12 Months to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 28, 2026, 4:01 PM EDT
Not listed Phase 4 Interventional

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

NCT01869309
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 28, 2026, 4:01 PM EDT